Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
The most significant opportunity lies in the cyclical restocking inflection across Latin America and North America.
Distributor credit defaults and persistent agricultural inventory lockup in Brazil preventing wholesale revenue growth from inflecting positive through FY2027.
We rate FMC Corporation Strong Buy, as the share price at analysis date of $5.66 (as of 2026-10-16) represents 320.1% upside to our Fair value of $23.78, offering substantial capital appreciation potential at the cyclical trough of an unprecedented crop chemical channel destocking cycle,.
A Strong Buy rating indicates that FMC Corporation presents exceptional risk-adjusted total return potential for long-term investors, warranting a proactive capital allocation for portfolios seeking cyclical turnaround exposure.
Shares trade at $5.66 (as of 2026-10-16), reflecting a profound cyclical discount to our Fair value of $23.78 and Potential value of $32.51, which captures 320.1% upside as distributor order patterns normalize.
The primary catalyst for multi-year value creation is the natural equilibrium of channel destocking and demand recovery for core diamide insecticides, which generated $1,572.7M in FY2025. As distributor inventories clear in Latin America and North America, wholesale replenishment will drive cyclical volume recovery, restoring operating leverage and expanding profit margins toward historical mid-cycle levels, moving equity value toward Fair value of $23.78.6
Shares trade at $5.66 (as of 2026-10-16) against Fair value of $23.78, providing 320.1% upside as normalized earnings power re-emerges.
Proprietary formulations and regulatory barriers protect core insecticide revenue ($1,572.7M in FY2025), defending gross profit of $1,283.0M.56
Distributor stock equilibrium in Brazil ($1,116.5M FY2025 sales) will re-establish wholesale procurement aligned with steady farm-gate consumption.6
FMC Corporation warrants a Strong Buy rating because shares trade at an acute cyclical trough discount to intrinsic value while its patented diamide insecticide franchise and post-destocking channel recovery support a robust multi-year operational turnaround,.
FMC Corporation is a global agricultural sciences company dedicated to crop protection and agricultural innovation. The company discovers, develops, and delivers chemical and biological solutions that enhance farm productivity and land resilience across diversified farming regions worldwide.
The company operates across all three major crop protection chemical categories: insecticides, herbicides, and fungicides. Insecticides and herbicides constitute the core of the portfolio, targeting broad-spectrum insect infestations and difficult-to-control weeds, while fungicides protect high-value crops. FMC also invests in biologicals, crop nutrition, and seed treatment products under its plant health portfolio, alongside specialty pest control solutions for non-agricultural applications.
A severe cyclical stress test models the joint realization of prolonged Latin American distributor destocking and aggressive generic diamide pricing erosion. In this downside scenario, Brazilian revenue fails to rebound from $1,116.5M, operating cash flow remains trapped near the -$80.2M recorded in FY2025, and insecticide pricing contracts by more than 10%. Under these conditions, annual operating profit stagnates near $280M, preventing the company from amortizing its $4,402.7M total debt burden. With pre-tax cost of debt already at 19.64%, interest coverage drops below covenant limits, necessitating dilutive equity restructuring or asset divestitures at fire-sale valuations, which would compress intrinsic value toward the bear-case forward earnings anchor of $8.46 per share.
A downside path exists wherein farm-gate credit insolvencies and distributor liquidity constraints in Brazil delay channel absorption well beyond expectations. Concurrent price competition from generic active ingredient formulators prevents operating margins from recovering, while elevated debt service requirements absorb operational cash generation. This qualitative risk case reflects persistent cyclical stagnation rather than operational recovery.
Brazil generated $1,116.5M in FY2025. FY2025 operating cash flow was -$80.2M due to grower credit defaults and channel lockup. If Brazilian revenue fails to rebound and contracts further, working capital remains trapped, forcing debt covenant renegotiation under $4,402.7M total debt.46
De vijf ontwikkelingen die onze beleggingsthese zouden verzwakken.
Persistent channel overhang and credit defaults in Brazilian agriculture prevent distributor order replenishment, stranding working capital.
Huidig:$1,116.5M in FY2025
Waarschuwing als<= 0.0% YoY growth through FY2027
FMC Corporation maintains a narrow economic moat rooted in proprietary crop protection chemistry, intellectual property estates, and extensive global regulatory registrations. The centerpiece of the franchise is its proprietary diamide insecticide portfolio, anchored by rynaxypyr and cyazypyr active ingredients. In FY2025, insecticides generated $1,572.7M, representing 45.4% of consolidated net sales,. Despite primary active ingredient patent expiries in selected jurisdictions, FMC retains substantial defensive protection through secondary formulation patents, proprietary mixture combinations, and trade secret manufacturing processes that generic formulators cannot easily replicate.
Customer switching costs in agricultural crop protection are driven by rigorous local product registrations and established grower reliance on high-efficacy treatment regimens. In developed agricultural markets such as North America ($1,102.2M FY2025 sales) and EMEA ($871.5M FY2025 sales), regulatory agencies (EPA and EFSA) enforce stringent data requirements and lengthy approval timelines that restrict unapproved imported technical chemistries. Growers faced with high crop investment costs hesitate to substitute unproven generic alternatives when combating yield-threatening pests.
Nevertheless, the moat is bounded as Narrow rather than Wide due to the finite duration of patent protection and aggressive generic competition originating in Asia. Peer chemical producers face similar margin frictions, and the entry of generic active ingredients into major emerging crop markets such as Brazil ($1,116.5M FY2025 revenue) exerts ongoing pricing friction that prevents FMC from extracting permanent economic rents above historical mid-cycle levels.
Prior to the recent industry-wide destocking correction, FMC earned consistent economic profits above its cost of equity. In FY2025, operating income collapsed to -$1,628.3M due to cyclical inventory liquidation and non-cash goodwill and asset impairments, pushing return on invested capital deeply into negative territory. Capital-weighted WACC is elevated at 14.17%, reflecting an 83.34% debt weight and a 19.64% pre-tax cost of debt on $4,402.7M total debt. As revenue normalizes toward $3,542.4M in FY2027 and operating margins recover toward historical mid-cycle averages, ROIC is projected to surpass the cost of equity, generating positive economic spread on normalized operations.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($23.78). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $116.3M after modeled reinvestment of $107.4M, with terminal value at 64.9% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base scenario envisions our primary valuation target of $23.78, assigned a 55.0% probability weighting and offering an implied return of 320.1% from the analysis price of $5.66 (as of 2026-10-16). In this pathway, distributor inventory destocking in Latin America and North America concludes through FY2027, restoring wholesale procurement toward equilibrium with grower field applications. Operating margins normalize toward historical mid-cycle levels as operating leverage returns across manufacturing assets, while proprietary formulations defend diamide insecticide market share.
An operational upside beat would confirm that channel inventory liquidation has reached completion and distributor re-orders are accelerating ahead of schedule, validating normalized mid-cycle margin expansion.
In-line performance indicates that distributor destocking is progressing according to the baseline recovery path without evidence of structural market share erosion.
A material earnings miss would signal that distributor destocking is extending further and credit stress is impairing customer procurement, threatening cash flow generation and debt service.
Reported earnings quality reflects cyclical trough distortions characterized by substantial non-cash asset impairment charges and negative operating cash conversion driven by channel inventory accumulation. Core manufacturing gross margins have shown relative durability, indicating that underlying unit product profitability remains sound once distributor destocking concludes. Working capital liquidation and normalization of trade receivables in South America represent the primary operational drivers required to re-establish high-quality, cash-backed earnings.
Consensus earnings and revenue estimates have faced downward revisions over recent cycles, reflecting extended inventory liquidation in Latin America and cautious procurement by agricultural retailers ahead of the seasonal application window.
Inventory liquidation in Brazil determines when wholesale re-orders begin, which drives consolidated sales growth and operating margin recovery.
Cash flow generation was severely impacted in FY2025 by working capital lockup and retail credit defaults in Latin America, resulting in operating cash flow of -$80.2M. This contrasts with historical cash generation capabilities, such as the $720.0M free cash flow achieved in FY2021. Because gross profit remained resilient at $1,283.0M, the liquidation of excess channel inventory and collection of overdue trade receivables will release substantial working capital through FY2026 and FY2027, restoring positive operating cash flow conversion.457
FMC has re-aligned its capital allocation framework to prioritize balance sheet preservation and debt de-leveraging during the cyclical trough. With total debt at $4,402.7M against a of $880.4M, management has curtailed discretionary growth and paused share buybacks. Capital allocation will direct operational toward debt amortization to reduce pre-tax from 19.64%, thereby expanding equity multiple headroom.
In FY2025, ROIC turned sharply negative due to an operating loss of -$1,628.3M and significant non-cash impairments. However, as operating margins recover toward 8.5% in FY2026 ($283.1M EBIT) and 11.5% in FY2027 ($407.4M EBIT), return on invested capital is modeled to recover toward mid-cycle averages of 13.5% to 15.5% by FY2028-FY2030.
ROIC is projected to comfortably exceed the moderate cost of equity of 7.44% as operating earnings normalize. However, total capital spread will remain constrained relative to the elevated WACC of 14.17% until high-cost debt ($4,402.7M at 19.64% pre-tax cost,) is systematically amortized.
| Omzet | US$ 867.100.000 |
|---|---|
| Kostprijs van de omzet | US$ 525.000.000 |
| Brutowinst | US$ 342.100.000 |
| Bedrijfskosten | US$ 461.800.000 |
| Bedrijfsresultaat | US$ -119.700.000 |
| Niet-operationele posten en belastingen | US$ -66.900.000 |
| Nettowinst | US$ -186.600.000 |
| Totale activa | US$ 9.687.200.000 |
|---|---|
| Liquide middelen | US$ 584.500.000 |
| Vlottende activa | US$ 4.959.000.000 |
| Totale verplichtingen | US$ 7.588.300.000 |
| Kortlopende verplichtingen | US$ 3.755.300.000 |
| Eigen vermogen | US$ 2.098.900.000 |
| Nettowinst | US$ 341.100.000 |
|---|---|
| Operationele instroom | US$ 671.100.000 |
| Afschrijvingen en amortisatie | US$ 176.300.000 |
| Aandelenbeloning | US$ 23.800.000 |
| Overige operationele aanpassingen | US$ 129.900.000 |
| Operationele kasstroom | US$ 671.100.000 |
| Beschikbare liquide middelen | US$ 1.237.100.000 |
| Beginstand liquide middelen | US$ 302.400.000 |
| Investeringsinstroom | US$ 263.600.000 |
| Financieringsuitstroom | US$ 870.100.000 |
| Betaalde dividenden | US$ 290.600.000 |
| Netto schuldaflossing | US$ 576.700.000 |
| Overige financieringsactiviteiten | US$ 2.800.000 |
| Wisselkoerseffect | US$ 9.700.000 |
| Eindstand liquide middelen | US$ 357.300.000 |
| Investeringskasstroom | US$ 263.600.000 |
| Financieringskasstroom | US$ -870.100.000 |
Bron: SEC EDGAR · Ingediend 2026-02-27 · SEC EDGAR
| Omzet per bedrijfscategorie | Omzet | Aandeel | j-o-j |
|---|---|---|---|
| Insecticides | US$ 1,6 mld. | 45,4% | -33,9% |
| Herbicides | US$ 1,2 mld. | 36% | -2,6% |
| Fungicides | US$ 362,8 mln. | 10,5% | 2,9% |
| Plant Health | US$ 190,9 mln. | 5,5% | -4,8% |
| Product And Service Other | US$ 94,1 mln. | 2,7% | 171,2% |
Financiële momentopname gebruikt in de analyse van 2026-10-17.
| Periode | Omzet | EBITDA | Nettowinst | Operationele kasstroom | Vrije kasstroom | Investeringen | Afschrijvingen en amortisatie | Aandelenbeloning | Aandeleninkoop | Betaalde dividenden | Netto schuldemissie | Investeringskasstroom | Financieringskasstroom | Beginstand liquide middelen | Eindstand liquide middelen | Kas en beleggingen | Totale schuld | Operationele marge | ROIC | WACC | ROIC−WACC-spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$ 2,5 mld. | US$ 344,9 mln. | US$ 209,1 mln. | US$ 497,8 mln. | US$ 406,6 mln. | US$ 91,2 mln. | US$ 100,6 mln. | US$ 20,2 mln. | US$ 11,2 mln. | US$ 88,6 mln. | — | -US$ 155,2 mln. | -US$ 377 mln. | — | US$ 60,2 mln. | US$ 64,2 mln. | US$ 1,8 mld. | 10,5% | — | 6,7% | — |
| 2017-12-31 | US$ 2,5 mld. | US$ 370,5 mln. | US$ 535,8 mln. | US$ 335,5 mln. | US$ 297,2 mln. | US$ 38,3 mln. | US$ 97,8 mln. | US$ 21,1 mln. | US$ 0 | US$ 88,8 mln. | — | -US$ 1,3 mld. | US$ 1,2 mld. | US$ 60,2 mln. | US$ 281,8 mln. | US$ 283 mln. | US$ 3,1 mld. | 6,3% | — | 6,6% | — |
| 2018-12-31 | US$ 4,3 mld. | US$ 892,7 mln. | US$ 502,1 mln. | US$ 368,4 mln. | US$ 285,4 mln. | US$ 83 mln. | US$ 150,2 mln. | US$ 22,5 mln. | US$ 200 mln. | US$ 89,2 mln. | — | -US$ 130,9 mln. | -US$ 363,3 mln. | US$ 281,8 mln. | US$ 134,4 mln. | US$ 163,5 mln. | US$ 2,5 mld. | 17,3% | — | 6,3% | — |
| 2019-12-31 | US$ 4,6 mld. | US$ 964,8 mln. | US$ 477,4 mln. | US$ 488,5 mln. | US$ 394,6 mln. | US$ 93,9 mln. | US$ 150,1 mln. | US$ 25,6 mln. | US$ 400 mln. | US$ 210,3 mln. | — | -US$ 195,9 mln. | -US$ 124,2 mln. | US$ 134,4 mln. | US$ 339,1 mln. | US$ 339,1 mln. | US$ 3,1 mld. | 17,8% | — | 5,9% | — |
| 2020-12-31 | US$ 4,6 mld. | US$ 1 mld. | US$ 552,4 mln. | US$ 647,8 mln. | US$ 580,6 mln. | US$ 67,2 mln. | US$ 162,7 mln. | US$ 18,9 mln. | US$ 50 mln. | US$ 228,5 mln. | — | -US$ 200,4 mln. | -US$ 250,3 mln. | US$ 339,1 mln. | US$ 568,9 mln. | US$ 569 mln. | US$ 3 mld. | 19,3% | — | 4,8% | — |
| 2021-12-31 | US$ 5 mld. | US$ 1,2 mld. | US$ 739,6 mln. | US$ 820,1 mln. | US$ 720 mln. | US$ 100,1 mln. | US$ 170,9 mln. | US$ 17,8 mln. | US$ 400 mln. | US$ 247,2 mln. | — | -US$ 112 mln. | -US$ 747,9 mln. | US$ 568,9 mln. | US$ 516,8 mln. | US$ 520,5 mln. | US$ 2,8 mld. | 20,5% | — | 5,2% | — |
| 2022-12-31 | US$ 5,8 mld. | US$ 1,3 mld. | US$ 736,5 mln. | US$ 582,4 mln. | US$ 440,1 mln. | US$ 142,3 mln. | US$ 169,4 mln. | US$ 24,2 mln. | US$ 100 mln. | US$ 267,5 mln. | US$ 113,8 mln. | -US$ 266,4 mln. | -US$ 237,4 mln. | US$ 516,8 mln. | US$ 572 mln. | US$ 584,4 mln. | US$ 2,8 mld. | 19,7% | — | 7,4% | — |
| 2023-12-31 | US$ 4,5 mld. | US$ 786,2 mln. | US$ 1,3 mld. | -US$ 386,4 mln. | -US$ 520,3 mln. | US$ 133,9 mln. | US$ 184,3 mln. | US$ 25,9 mln. | US$ 75 mln. | US$ 290,5 mln. | US$ 699,3 mln. | -US$ 154,4 mln. | US$ 331,5 mln. | US$ 572 mln. | US$ 302,4 mln. | US$ 302,4 mln. | US$ 3,1 mld. | 12,4% | — | 7,5% | — |
| 2024-12-31 | US$ 4,2 mld. | US$ 827,9 mln. | US$ 341,1 mln. | US$ 671,1 mln. | US$ 603,2 mln. | US$ 67,9 mln. | US$ 176,3 mln. | US$ 23,8 mln. | US$ 0 | US$ 290,6 mln. | -US$ 576,7 mln. | US$ 263,6 mln. | -US$ 870,1 mln. | US$ 302,4 mln. | US$ 357,3 mln. | US$ 357,3 mln. | US$ 3,1 mld. | 11,9% | — | 8,1% | — |
| 2025-12-31 | US$ 3,5 mld. | -US$ 84,7 mln. | -US$ 2,2 mld. | -US$ 80,2 mln. | -US$ 176,5 mln. | US$ 96,3 mln. | US$ 173,6 mln. | US$ 24 mln. | US$ 0 | US$ 291,3 mln. | US$ 708,9 mln. | -US$ 99,7 mln. | US$ 386 mln. | US$ 357,3 mln. | US$ 584,5 mln. | US$ 584,5 mln. | US$ 3,4 mld. | -47,0% | — | — | — |
FMC Corporation (FMC) trades at 5.7x forward earnings against a peer median of 11.1x. Its EV/EBITDA of 17.3x compares with a peer median of 8.4x. The comparison uses 4 peers: The Mosaic Company, Corteva Inc., CF Industries Holdings Inc. and Celanese Corporation, as of 2026-10-17.
Global crop chemical channel inventories reached severe overhang following post-pandemic over-purchasing, leading to aggressive destocking across Brazil ($1,116.5M FY2025 revenue) and North America ($1,102.2M FY2025 revenue), resulting in consolidated revenue dropping to $3,467.4M and operating income to -$1,628.3M.56
In a cyclical upswing, distributor inventories reach depleted thresholds simultaneously across key agricultural regions. Strong grower commodity margins and elevated pest infestations stimulate urgent chemical restocking. Wholesale order volumes rebound rapidly above end-consumption rates, driving substantial operating leverage, widening gross margins, and generating robust free cash flow to accelerate balance sheet deleveraging.
In an extended bear cycle, persistent agricultural credit illiquidity and low farmer crop margins in South America sustain channel inventory freezes. Distributors refuse new order commitments, forcing aggressive price discounting on off-patent active ingredients and stranding manufacturing capacity. Consolidated revenue stagnates below historical mid-cycle levels, while high financial leverage severely constrains reinvestment.
The industry cycle view is demand-led and evidence-limited, reflecting global agricultural chemical inventory destocking across distribution channels. FMC is positioned as a pure-play crop protection leader with substantial exposure to insecticides ($1,572.7M in FY2025) and Latin America ($1,351.4M in FY2025). However, its high leverage of $4,402.7M total debt creates heightened vulnerability to cycle duration relative to diversified peers such as Corteva (CTVA operating margin 12.78%) or CF Industries (CF operating margin 49.33%).46
We recommend a measured allocation weighting within a cyclical or value-oriented portfolio. While the implied upside to Fair value of 320.1% is substantial, position sizing is bounded by high financial leverage and exposure to ongoing channel adjustments in Latin America.
Risk management must center on balance sheet leverage and working capital velocity. Given elevated debt levels, investors should avoid concentration risk, adhering strictly to the recommended portfolio allocation. Position reviews should be triggered if operating cash conversion fails to improve or if debt service ratios deteriorate.
Cyclical investors will find compelling value in a market leader trading at trough multiples while channel inventories reach equilibrium, creating strong operating leverage as wholesale volumes recover.
Value investors benefit from a significant margin of safety with 320.1% upside to Fair value of $23.78, supported by durable intangible assets and high customer switching costs in crop protection.
Conservative income-seeking investors should avoid the shares due to high debt weight of 83.34% and pre-tax cost of debt of 19.64%, which prioritize debt reduction over dividend growth.2
We recommend a Strong Buy rating on FMC Corporation, reflecting 320.1% upside from $5.66 (as of 2026-10-16) to our Fair value of $23.78,.
FMC trades at an acute cyclical trough valuation caused by historic distributor destocking across global crop chemical channels. As inventories reach equilibrium in Latin America and North America, demand for proprietary diamide insecticides will drive a multi-year recovery in revenue and operating margins, unlocking substantial shareholder value.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Insecticides contribute $1,572.7M (45.4% of total sales). Following patent expiries on rynaxypyr, generic technical active ingredient supply from Asian producers drives aggressive price deflation, preventing operating margin from recovering to the authored 15.5% target.56
FMC carries $4,402.7M of total debt against market cap of $880.4M with debt weight of 83.34%. Pre-tax cost of debt is already 19.64%. A credit rating downgrade or debt refinancing spike elevates WACC above 16%, crushing equity value.24
Analyst bear scenario assumes EPS growth stagnates at 2.0% annually with terminal P/E collapsing to 8.5x under persistent Latin American channel overhang, contrasting with the authored base case recovery of 19.08% in FY2027.1
Accelerated off-patent generic diamide penetration displacing proprietary formulations and permanently eroding insecticide pricing power.
Huidig:45.4% of total sales ($1,572.7M) in FY2025
Waarschuwing als< 40.0% of consolidated revenue
Refinancing friction on $4,402.7M total debt increases interest expense and threatens balance sheet restructuring.
Huidig:19.64% as of 2026-10-17
Waarschuwing als> 20.0%
Inability to release working capital from inventory and receivables continues operating cash drain, precluding voluntary debt amortization.
Huidig:-$80.2M in FY2025
Waarschuwing als<= $0.0M through FY2026
Fixed overhead deleveraging and competitive pricing pressure prevent operating margin recovery toward historical mid-cycle targets.
Huidig:-46.96% in FY2025
Waarschuwing als< 8.0% in FY2026
| Tightening customer credit terms, transitioning toward secured grain barter arrangements, and curtailing channel inventory shipments until retail inventories liquidate.4 |
Under the moderate discount rate, US$ 5,42 comes from forecast-period earnings and US$ 25,36 from the long-term value, totaling US$ 30,78.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Solve for the growth rate that makes the model value equal the report-date share price.
The Bull scenario models an upside valuation target of $32.51, assigned a 20.0% probability weighting and delivering an implied return of 474.4% from $5.66 (as of 2026-10-16). Under this trajectory, channel inventory depletion triggers an aggressive restocking cycle across South America, supported by robust pest pressure and expanding planted acreage. High-margin specialty formulations accelerate operating margin expansion beyond mid-cycle targets, while substantial free cash flow generation enables accelerated debt paydown.
Revenue stability in insecticides reveals whether proprietary formulations and local registration barriers successfully insulate gross margins from off-patent generic active ingredient competition.
Unwinding excess working capital restores operating cash generation, providing the essential liquidity required to service debt without external capital dilution.
Margin strength in North America and EMEA generates the baseline cash flow needed to support fixed corporate expenses during emerging market downturns.
Debt amortization reduces interest expense, expands equity valuation multiple headroom, and lowers corporate cost of capital.
| $3.72B |
| $3.87B |
| $3.98B |
| Revenue growth | -3.9% | 6.3% | 5.0% | 4.0% | 3.0% |
| Operating margin | 8.5% | 11.5% | 13.5% | 14.8% | 15.5% |
| Operating income | $283.15M | $407.37M | $502.12M | $572.50M | $617.56M |
| Tax rate | 21.0% | 21.0% | 21.0% | 21.0% | 21.0% |
| NOPAT | $223.69M | $321.82M | $396.68M | $452.27M | $487.87M |
| Reinvestment | $107.37M | $112.64M | $119.00M | $117.59M | $121.97M |
| Reinvestment rate (of NOPAT) | 48.0% | 35.0% | 30.0% | 26.0% | 25.0% |
| Free cash flow to firm | $116.32M | $209.18M | $277.67M | $334.68M | $365.90M |
| Terminal growth | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% |
Gross profit reached $1,283.0M (37.0% margin) in FY2025 on net revenue of $3,467.4M, despite operating income falling to -$1,628.3M due to asset impairments and fixed overhead deleverage.
Core chemical manufacturing and formulation economics retain sound unit profitability, ensuring that volume stabilization will swiftly restore operating income.
Operating cash flow deteriorated to -$80.2M in FY2025 due to trapped working capital in Latin America ($1,351.4M sales), compared to $720.0M FCF generated in FY2021.
Unwinding trapped channel inventories will liberate working capital, providing internal liquidity to fund debt service.
Analyst consensus projects FY2026 revenue of $3,331.21M and EPS of $1.21, expanding to $3,542.37M revenue and $1.44 EPS in FY2027.
The operational transition from trough losses to expanding profitability confirms the inflection point in normalized earnings power.
| Marge |
|---|
| FMC | FMC Corporation | $880.4M | 5.7x | 0.3x | 17.3x | -88.4% | — |
| MOS | The Mosaic Company | $6.0B | 12.0x | 0.5x | 6.9x | -5.1% | -0.1% |
| CTVA | Corteva Inc. | $8.6B | 11.4x | 1.7x | 17.3x | 4.3% | 12.8% |
| CF | CF Industries Holdings Inc. | $18.3B | 10.8x | 2.4x | 5.8x | 29.9% | 49.3% |
| CE | Celanese Corporation | $5.2B | 7.9x | 0.5x | 9.9x | -22.2% | 11.0% |
| negative |
| Grower margin volatility and local currency depreciation in emerging agricultural economies complicate distributor working capital and trade credit management. |
| Re-evaluate competitive moat durability against generic active ingredients and adjust terminal valuation multiples. |
| Operating Cash Flow Turnaround | Operating cash flow failing to turn positive on a trailing basis by FY2026, evaluated against FY2025 operating cash flow of -$80.2M. | Halt incremental position additions and assess liquidity risk under total debt of $4,402.7M.4 |
